Narval develops synthetic antibody mimetic proteins (AMP) to replace conventional antibodies on novel first-in-class immunotherapeutics, making them as affordable, flexible and easy to use as small molecule drugs. AMPs are 40 times smaller than a monoclonal antibody but with the same biological function. Our AMP can penetrate tissue barriers, generate limited immune reactions, can target very small and hard-to-reach antigens, and are heat resistant. These advantages gives our AMP technology the ability to develop immunotherapeutic drugs for disease applications that have been previously impossible to develop because of monoclonal antibody limitations. Our AMPs can be used to generate novel first-in-class antibody drugs to treat, for example, respiratory diseases with inhaled antibodies, eye diseases with non-invasive antibodies on eye drops or autoimmune and skin diseases with antibodies in transdermal controlled release patches.
Is this your company?
Something looks off?
